| CELCUITY INC. DL -,001 |
| USA |
| Gesundheit |
| US15102K1007 / A2JAAX |
| 7VR (Frankfurt) / CELC (NASDAQ) |
| FRA:7VR, ETR:7VR, 7VR:GR, NASDAQ:CELC |
| - |
| https://www.celcuity.com/ |
|
Celcuity Inc. is a clinical-stage biotechnology company focused on advancing oncology therapeutics and precision cancer diagnostics. The company develops innovative approaches to cancer treatment through its lead therapeutic candidate, gedatolisib, a..
>Volltext.. |
| 5558.09 Mio. EUR |
| 5503.52 Mio. EUR |
| - |
| -159.87 Mio. EUR |
| -165.44 Mio. EUR |
| -3.34 EUR |
| 277.42 Mio. EUR |
| 124.53 Mio. EUR |
| - |
| 11.65 |
| - |
| -51.68% |
| - |
| - |
| - |
| 2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 4.110.174 Euro. |
| CELCUITY |
| 02.06.26 |
|